A clinician-guided decision
Foundayo contains orforglipron, an oral GLP-1 receptor agonist. It is approved for use with a reduced-calorie diet and increased physical activity for adults with obesity, or adults with overweight and at least one weight-related condition.
Medication decisions are individual. A Resolve clinician can review your medical history, other medications, potential benefits and risks, and whether an oral option may be appropriate for your treatment plan.
For further independent medication information, visit Foundayo resources.